Evaluation of the effect of intranasal desmopressin spray on the complications of kidney biopsy in renal failure

Randomized Placebo-controlled trial of the effect of intranasal administration of desmopressin acetate on the bleeding complications after renal needle-biopsy sampling in patients with renal failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201019049075N1

Enrollment

Registered

2021-08-10

Start date

2019-12-22

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Bleeding. Condition 2: Kidney biopsy. Condition 3: Acute kidney failure. Postprocedural hemorrhage and hematoma of skin and subcutaneous tissue following other procedure Acute kidney failure, unspecified

Interventions

Intervention 1: The intervention group: The intervention group will receive high-concentration desmopressin spray nasally Octostim® (concentration of 150 micrograms per milliliter) (Ferring GmbH, Germ

patients weighing less than 50 kilograms, 150 micrograms (one nasal spray) per dose

patients weighing more than 50 kg, 300 micrograms (two nasally sprays one per nostril) per dose. Intervention 2: Control group: The control group will receive RINOSALTIN® nasal spray (0.65 percent sal

patients weighing less than 50 kilograms one nasal spray per dose

patients weighing more than 50 kg, two nasally sprays one per nostril per dose.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients referred for renal biopsy.

Exclusion criteria

Exclusion criteria: Serum creatinine equal or more than 2 mg/dl serum sodium less than 130 meq/liter taking anti-platelets or anticoagulants thrombocytopenia history of kidney cancer solitary kidney small size kidneys active urinary tract infection abnormal prothrombin time Patients who have received any kind of renal replacement therapy (hemodialysis or peritoneal dialysis) within the week before the biopsy Blood pressure more than 160/90 mmHg

Design outcomes

Primary

Measure	Time frame
The proportion of the patients who develop hematoma. Timepoint: 24 hours post biopsy. Method of measurement: Ultrasound.;The proportion of the patients who develop hematuria. Timepoint: 24 hours post biopsy. Method of measurement: Urinalysis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahrokh Ezzatzadegan Jahromi

Shiraz University of Medical Sciences

shjahromi@sums.ac.ir+98 71 3647 4316

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026